相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J. Giffin et al.
CLINICAL CANCER RESEARCH (2021)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).
Horst-Dieter Hummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer
Scott T. Tagawa et al.
CANCER (2019)
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise
Semini Sumanasuriya et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
Thomas Langbein et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
Katharina Luckerath et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer
Kasey Jividen et al.
BMC CANCER (2018)
Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro
Ling Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Wolfgang P. Fendler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Giuseppe Galletti et al.
CANCER TREATMENT REVIEWS (2017)
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Isabel Coutinho et al.
ENDOCRINE-RELATED CANCER (2016)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Kevin J. Hamblett et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Synergistic Co-Targeting of Prostate-Specific Membrane Antigen and Androgen Receptor in Prostate Cancer
Jose D. Murga et al.
PROSTATE (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research
Benjamin T. Ristau et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
Colin C. Pritchard et al.
NATURE COMMUNICATIONS (2014)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
International Harmonization of Toxicologic Pathology Nomenclature: An Overview and Review of Basic Principles
Peter C. Mann et al.
TOXICOLOGIC PATHOLOGY (2012)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models
SR Denmeade et al.
PROSTATE (2003)
分享论文
